Skip to content

Comparative Study of Radiofrequency Renal Denervation versus Ultrasound Renal Denervation for the Treatment of Primary Hypertension

Comparative Study of Radiofrequency Renal Denervation versus Ultrasound Renal Denervation for the Treatment of Primary Hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114989
Enrollment
Unknown
Registered
2025-12-19
Start date
2025-12-20
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hypertension

Interventions

Ultrasound group:Ultrasound group
Radiofrequency group (RF group):Radiofrequency group (RF group)

Sponsors

SUN YAT-SEN MEMORIAL HOSPITAL
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1.Age >=18 years and =3 months, after treatment with protocol-specified antihypertensive medications for at least 28 days (at least two types), clinic SBP >=140mmHg and clinic DBP >=90mmHg, with concurrent 24h-SBP >=135mmHg; 3.Agree to comply with the research process and sign informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with secondary hypertension; 2.History of previous renal artery interventional treatment, such as stenting, etc.; renal artery lesions or morphological variants, including: aneurysm, stenosis, severe renal artery calcification, dissection, multiple renal arteries, etc.; 3.Occurrence of myocardial infarction, unstable angina, syncope, cerebrovascular accident, intermittent claudication, extensive atherosclerosis with history of intravascular thrombosis within the recent 6 months; 4.Concurrent cardiac valvular disease with significant hemodynamic changes; 5.Concurrent refractory pulmonary hypertension; 6.Estimated glomerular filtration rate (eGFR) 1.5); 8.History of ICD (implantable cardioverter defibrillator); 9.Acute or severe systemic infection; 10.Concurrent type 1 diabetes mellitus;Other diseases requiring long-term oxygen therapy or mechanical ventilation besides nocturnal sleep apnea; 11.Contrast agent allergy; 12.Pregnant, lactating, or women planning pregnancy; 13.Alcohol and other substance addiction, psychiatric patients; 14.Other diseases that may adversely affect subject or clinical study safety; 15.Patients already participating in other drug or device clinical studies; 16.Patients deemed unsuitable for participation in this clinical study by the investigator.

Design outcomes

Primary

MeasureTime frame
24-hour ambulatory blood pressure;

Secondary

MeasureTime frame
Office blood pressure;

Countries

China

Contacts

Public ContactHaifeng Zhang

SUN YAT-SEN MEMORIAL HOSPITAL

zhanghf9@mail.sysu.edu.cn+86 20 81332361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026